{
}
Last week, National Councillor Eric Nussbaumer participated in a session report organized by Lars Trachsler, President of the SP, providing attendees with direct insights from the Federal Parliament. The event also featured representatives from Credit Suisse and other SP members.
UBS has maintained a "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton highlighted current prescription trends in the U.S. for the GLP-1 active ingredient, known for its appetite-suppressing effects.
UBS shares received strong support from analysts last month, with four experts recommending a buy. The average price target is CHF 36.25, indicating a potential increase of CHF 9.38 from the current price of CHF 26.87. The six-month rating trend remains positive.
UBS shares fell by 4.3% to CHF 26.74 at midday, marking a decline from CHF 27.50 at the start of the trading day. The stock is currently 22.96% below its 52-week high of CHF 32.88 and 15.74% above its 52-week low of CHF 22.53. Despite a drop in revenue of 4.90% in the last quarter, earnings per share improved to CHF 0.21 from CHF -0.38 a year prior.
Three years ago, UBS shares were priced at CHF 18.15. An investment of CHF 10,000 would have resulted in 551,116 shares, now valued at CHF 15,398.18, reflecting a 53.98% increase, with the current share price at CHF 27.94 and a market capitalization of CHF 88.86 billion.
UBS has maintained a "Sell" rating for Zurich Insurance Group, setting a target price of 535 Swiss francs. Analyst Will Hardcastle favors life insurers over non-life insurers in Europe, highlighting Prudential, Aviva, AXA, Swiss Re, and Beazley as preferred stocks in his recent sector report.
Deutsche Bank has raised its price target for Alcon Inc. to CHF96 from CHF92, maintaining a Buy rating following the company's positive Capital Markets Day. Alcon, valued at $47.4 billion, anticipates organic sales growth of 6-8% and EPS growth of 12-15%, supported by upcoming product launches in surgical eye care and pharmaceuticals. Other analysts have also increased their targets, reflecting strong confidence in Alcon's innovative pipeline and long-term growth potential.
UBS shares, valued at CHF 18.15 three years ago, have seen a significant increase, with an investment of CHF 10,000 now worth CHF 15,398.18, reflecting a 53.98% gain. As of March 28, 2025, the shares are trading at CHF 27.94, contributing to a market valuation of CHF 88.86 billion.
UBS has maintained a 'Sell' rating for Zurich, setting a target price of 535 Swiss francs. Analyst Will Hardcastle favors life insurers over non-life insurers in the European sector, highlighting Prudential, Aviva, AXA, Swiss Re, and Beazley as preferred stocks.
An amendment to the law delays the tightening of capital adequacy requirements for UBS, providing the bank with a reprieve of three to four years. This shift, influenced by lobbying efforts, allows UBS to postpone raising CHF 15 to 25 billion in new equity capital, while simultaneously engaging in share buybacks that could increase risk and reduce stability.
Swiss Franc
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Federal Council and Credit Suisse Discuss Key Issues at Session Report
00:34 01.04.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
22:34 31.03.2025
analysts recommend buy for UBS shares with target price of 36.25 CHF
20:00 31.03.2025
ubs shares decline as investors react to latest trading results
18:02 31.03.2025
ubs investment yields significant profit over three years
14:08 31.03.2025
ubs maintains sell rating on zurich insurance with target price of 535 francs
Swiss Franc
Swiss Re AG
Zurich Insurance Group AG
Beazley plc
AXA SA
Prudential plc
CHE
Will Hardcastle
Show more
13:01 31.03.2025
Deutsche Bank raises Alcon price target amid strong growth projections and innovations
12:55 31.03.2025
investment in UBS shares yields significant returns over three years
11:28 31.03.2025
ubs maintains sell rating on zurich with target price of 535 francs
11:01 31.03.2025
UBS Gains Delay in Capital Adequacy Requirements Amid Lobbying Efforts
10:36 31.03.2025
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Industry Mergers & Acquisitions
Workplace Trends
Global Financial Events
Banking Regulations
Retail and Consumer Goods
Finance Mergers & Acquisitions
CEO Changes
Market Analysis and Predictions
Government Policies
Startups & Entrepreneurship
Global Trade Developments
Financial Scams and Security
Private Equity Deals
Central Bank Actions
Supply Chain Management
Government Economic Policies
Domestic Politics
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
Barclays PLC
Credit Suisse Lux Digital Healt
Bank of America Corporation
Deutsche Bank Money Market PP
UBS Group AG
BNP Paribas SA
Wells Fargo & Company
The Goldman Sachs Group, Inc.
Apple Inc.
Commerzbank AG
Banco Santander, S.A.
UniCredit S.p.A.
Danske Bank A/S
NVIDIA Corporation
Amazon.com, Inc.
SpaceXCoin USD
HSBC Holdings plc
HSBC HOLDINGS
Currencies:
United States Dollar
Euro
British Pound Sterling
Chinese Yuan
Swiss Franc
Indian Rupee
Japanese Yen
Danish Krone
Hong Kong Dollar
Australian Dollar
South Korean Won
Singapore Dollar
Russian Ruble
Offshore Chinese Yuan
Canadian Dollar
Mexican Peso
Indonesian Rupiah
Turkish Lira
Chilean Peso
United Arab Emirates Dirham
People: